scholarly journals Hepatic Arterial Embolization Versus Chemoembolization in Patients With Liver Metastases of a Digestive Neuroendocrine Tumors

2011 ◽  
Vol 140 (5) ◽  
pp. S-875
Author(s):  
Frédérique Maire ◽  
Catherine Lombard-Bohas ◽  
Dermot O'Toole ◽  
Marie-Pierre Vullierme ◽  
Vinciane Rebours ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumors ◽  
Arterial Embolization ◽  
Hepatic Arterial Embolization

scholarly journals Hepatic Arterial Embolization for the Treatment of Metastatic Neuroendocrine Tumors

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Eric Lee ◽  
H. Leon Pachter ◽  
Umut Sarpel
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumors ◽  
Survival Rates ◽  
Arterial Embolization ◽  
Progression Free Survival ◽  
Term Survival ◽  
Free Survival ◽  
Hepatic Arterial Embolization

Neuroendocrine tumors (NETs) have a high predilection for metastasizing to the liver and can cause severe debilitating symptoms adversely affecting quality of life. Although surgery remains the treatment of choice, many liver metastases are inoperable at presentation. Hepatic arterial embolization procedures take advantage of the arterial supply of NET metastases. The goals of these therapies are twofold: to increase overall survival by stabilizing tumor growth, and to reduce the morbidity in symptomatic patients. Patients treated with hepatic arterial embolization demonstrate longer progression-free survival and have 5-year survival rates of nearly 30%. The safety of repeat embolizations has also been proven in the setting of recurrent symptoms or progression of the disease. Despite not being curative, hepatic arterial embolization should be used in the management of NETs with liver metastases. Long-term survival is not uncommon, making aggressive palliation of symptoms an important component of treatment.

scholarly journals Small Bowel and Colorectal Carcinoids

2018 ◽  
Vol 31 (05) ◽  
pp. 301-308 ◽  
Author(s):  
Raphael Byrne ◽  
Rodney Pommier
Keyword(s):  
Small Bowel ◽  
Neuroendocrine Tumors ◽  
Cytoreductive Surgery ◽  
Mammalian Target Of Rapamycin ◽  
Arterial Embolization ◽  
Angiogenesis Inhibitors ◽  
Somatostatin Analogues ◽  
Interferon Α ◽  
Peptide Receptor ◽  
Hepatic Arterial Embolization

AbstractNeuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.

Successful Control of Liver Metastases From Pancreatic Solid-Pseudopapillary Neoplasm (SPN) Using Hepatic Arterial Embolization

2014 ◽  
Vol 38 (2) ◽  
pp. 479-483 ◽  
Author(s):  
Elena G. Violari ◽  
Lynn A. Brody ◽  
Anne M. Covey ◽  
Joseph P. Erinjeri ◽  
George I. Getrajdman ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Arterial Embolization ◽  
Solid Pseudopapillary Neoplasm ◽  
Successful Control ◽  
Hepatic Arterial Embolization

Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases

2007 ◽  
Vol 31 (2) ◽  
pp. 299-307 ◽  
Author(s):  
Paresh P. Kamat ◽  
Sanjay Gupta ◽  
Joe E. Ensor ◽  
Ravi Murthy ◽  
Kamran Ahrar ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Large Volume ◽  
Arterial Embolization ◽  
Hepatic Arterial Embolization

scholarly journals Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study

2012 ◽  
Vol 96 (4) ◽  
pp. 294-300 ◽  
Author(s):  
Frédérique Maire ◽  
Catherine Lombard-Bohas ◽  
Dermot O’Toole ◽  
Marie-Pierre Vullierme ◽  
Vinciane Rebours ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Randomized Study ◽  
Arterial Embolization ◽  
Prospective Randomized Study ◽  
Endocrine Tumors ◽  
Well Differentiated ◽  
Hepatic Arterial Embolization

scholarly journals Hepatic arterial embolization in patients with neuroendocrine tumors

2014 ◽  
Vol 33 (1) ◽  
pp. 43 ◽  
Author(s):  
Michela Del Prete ◽  
Francesco Fiore ◽  
Roberta Modica ◽  
Vincenzo Marotta ◽  
Francesca Marciello ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Arterial Embolization ◽  
Hepatic Arterial Embolization

Metastatic Digestive Neuroendocrine Tumors: The Role of Hepatic Arterial Embolization/Chemoembolization

2011 ◽  
pp. P3-249-P3-249
Author(s):  
Joana Couto ◽  
Ana Paula Santos ◽  
Raquel Gomes Martins ◽  
Maria Jose Sousa ◽  
Maria Jose Bento ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Arterial Embolization ◽  
Hepatic Arterial Embolization

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors

Cancer ◽  
2005 ◽  
Vol 104 (8) ◽  
pp. 1590-1602 ◽  
Author(s):  
Sanjay Gupta ◽  
Marcella M. Johnson ◽  
Ravi Murthy ◽  
Kamran Ahrar ◽  
Michael J. Wallace ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Arterial Embolization ◽  
Hepatic Arterial Embolization

scholarly journals Selective Arterial Embolization of Liver Metastases from Gastrinomas: A Single-Centre Experience

2013 ◽  
Vol 2013 ◽  
pp. 1-8
Author(s):  
Anneke P. J. Jilesen ◽  
Heinz Josef Klümpen ◽  
Olivier R. C. Busch ◽  
T. M. van Gulik ◽  
Krijn P. van Lienden ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Neuroendocrine Tumors ◽  
Treatment Strategies ◽  
Arterial Embolization ◽  
Individual Treatment ◽  
Single Centre Experience ◽  
Radiological Response ◽  
Liver Embolization ◽  
Postembolization Syndrome ◽  
Prospective Database

Background. Gastrinomas are rare functional neuroendocrine tumors causing the Zollinger-Ellison syndrome (ZES). At presentation, up to 25% of gastrinomas are metastasized, predominantly to the liver. Embolization of liver metastases might reduce symptoms of ZES although a postembolization syndrome can occur. In this study, the results of embolization are presented, and the literature results are described. Methods. From a prospective database of pancreatic neuroendocrine tumors, all patients with liver metastatic gastrinomas were selected if treated with arterial embolization. Primary outcome parameters were symptom reduction, complications, and response rate. The literature search was performed with these items. Results. Three patients were identified; two presented with synchronous liver metastases. All the three patients had symptoms of ZES before embolization. Postembolization syndrome occurred in two patients. Six months after embolization, all the 3 patients had a clinical and complete radiological response; a biochemical response was seen in 2/3 patients. From the literature, only a small number of gastrinoma patients treated with liver embolization for liver metastases were found, and similar results were described. Conclusion. Selective liver embolization is an effective and safe therapy for the treatment of liver metastatic gastrinomas in the reduction of ZES. Individual treatment strategies must be made for the optimal success rate.

Sign in / Sign up

Export Citation Format

Share Document